We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Breast Conservation Surgery Often Requires Further Interventions

By HospiMedica International staff writers
Posted on 24 Nov 2014
A new study reveals that patients undergoing breast conservation surgery (BCS) have high repeat surgery rates, probably due to a lack of consensus on sufficient margin width.

Researchers at the University of Wisconsin (Madison, USA) analyzed data from the US National Cancer Data Base regarding 316,114 patients who underwent BCS from 2004–2010, excluding patients initially treated with chemotherapy or those diagnosed by excision biopsy. More...
The results showed that 76.4% of the patients underwent a single lumpectomy, compared with 23.6% having at least one additional operation after their BCS. The researchers found that the number of patients undergoing additional procedures decreased over time, from 25.4% to 22.7%.

The study showed that of the repeat surgery, 62.1% of patients had a completion lumpectomy, while 37.9% required a mastectomy. Rates of repeat surgery varied between different institutions; academic centers were 19% more likely to perform further operations than community centers. Other independent predictors of repeat surgeries were age, race, insurance status, comorbidities, histologic subtype, estrogen receptor status, pathologic tumor size, node status, tumor grade, and volume of breast cancer cases.

Age was inversely associated with repeat surgery, decreasing from 38.5% in patients 18 to 29 years old to 16.5% in those older than 80 years. In contrast, larger tumor size was linearly associated with a higher repeat surgery rate. When examined geographically, facilities in the Mountain region were significantly less likely to perform repeat surgery compared with those in the Northeastern United States, with respective rates of 18.4% and 26.5%. The study was published on November 12, 2014, in JAMA Surgery.

“At the root of the variability in repeat surgery rates for BCS is the lack of standardization of an acceptable margin width. The tumor margin width that will provide the lowest local recurrence rate has not been established in a randomized clinical trial setting,” concluded lead author Lee Wilke, MD, and colleagues of the School of Medicine and Public Health. “Until recently, no nationally or internationally accepted guidelines for an adequate margin width for invasive or noninvasive breast cancer have been available. This lack of a consensus has led to variable rates of re-excision and ranges in rates of 0% to 60%.”

Related Links:

University of Wisconsin



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Mammography System (Analog)
MAM VENUS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.